[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cell Origin Biotech (Hangzhou) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":20},"100559324","sy001-targets-mesothelin-in-a-single-arm-dose-increasing-setting-in-subjects-with-advanced-solid-tumors-100559324",false,"NCT06562647","SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors","An Exploratory Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SY001 Injection Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Patients with pathologically diagnosed advanced ovarian cancer\u002Fpancreatic cancer who have failed at least 1 prior lines treatment, and tumor tissue samples were positive for mesothlin IHC staining;\n2. According to the RECIST 1.1, there is measurable tumor lesions (non-lymph node lesion 10mm in length or lymph node lesion 15mm in diameter measured by CT or MRI, with scan layer thickness 5mm);\n3. Eastern Cooperative Oncology Group (ECOG) score of 2 and satisfactory major organ functions;\n4. Estimated life expectancy \\>3 months;\n5. Female patients of childbearing age must undergo a serum pregnancy test at screening and prior to pretreatment and the results must be negative, and are willing to use a very effective and reliable method of contraception within 1 year after the last study treatment.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Any uncontrollable active infection, including but not limited to active tuberculosis, HBV infection;\n3. Patients who have a history of other mesothelin-targeting therapy;\n4. Patients who have a history of autoimmune disease;\n5. The investigator assessed that the patient was unable or unwilling to comply with the requirements of the study protocol.","FEMALE","18 Years","75 Years",{"count":20,"type":21},2,"ESTIMATED","INTERVENTIONAL",[24],"NA","Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.",[27,28],"Treatment Related Cancer","Ovarian Cancer","RECRUITING","2026-02-12",{"date":32,"type":33},"2026-02-13","ACTUAL",{"date":35,"type":33},"2023-04-12",{"date":37,"type":21},"2027-12",{"name":39,"class":40},"Cell Origin Biotech (Hangzhou) Co., Ltd.","INDUSTRY",""]